meta
|
evidence
oncology
Living systematic review and meta-analysis
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - maintenance (M)
2
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
5
Extensive stage SCLC (Es-SCLC) - 2nd line (L2)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
durvalumab based treatment
durvalumab plus etoposide and platin
pembrolizumab based treatment
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
durvalumab plus tremelimumab plus SoC